VivoSim Labs (FRA:4OR) Return-on-Tangible-Equity: -187.36% (As of Dec. 2025)


FRA:4OR VivoSim Labs Inc FRA:4OR
39 GF Score
Price €3.49
GF Value €8.71
! 4 Warning Signs
View Full Analysis

What is VivoSim Labs Return-on-Tangible-Equity?

VivoSim Labs FRA:4OR 39 Return-on-Tangible-Equity is -187.36% as of Dec. 2025. GuruFocus rates FRA:4OR with a GF Score™ of 39/100 and a GF Value™ of €8.71. The stock has 4 warning signs investors should review. Among 1,201 Biotechnology companies, VivoSim Labs ranks better than 63.36% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. VivoSim Labs's annualized net income for the quarter that ended in Dec. 2025 was €-9.19 Mil. VivoSim Labs's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €4.91 Mil. Therefore, VivoSim Labs's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -187.36%.

The historical rank and industry rank for VivoSim Labs's Return-on-Tangible-Equity or its related term are showing as below:

FRA:4OR' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -155   Med: -63.41   Max: -19.23
Current: -19.23

During the past 13 years, VivoSim Labs's highest Return-on-Tangible-Equity was -19.23%. The lowest was -155.00%. And the median was -63.41%.

FRA:4OR's Return-on-Tangible-Equity is ranked better than
63.36% of 1201 companies
in the Biotechnology industry
Industry Median: -42.4 vs FRA:4OR: -19.23

VivoSim Labs  (FRA:4OR) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


VivoSim Labs Return-on-Tangible-Equity Related Terms


VivoSim Labs Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs Return-on-Tangible-Equity Chart

VivoSim Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -49.57 -34.45 -77.23 -153.11 -35.35

VivoSim Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -718.78 504.37 -109.71 -121.39 -187.36

FRA:4OR vs SLXN, CDT, CLDI: Return-on-Tangible-Equity Comparison

For the Biotechnology subindustry, VivoSim Labs's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VivoSim Labs Return-on-Tangible-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's Return-on-Tangible-Equity falls into.


FRA:4OR
39GF Score
VivoSim Labs Inc FRA:4OR
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs Return-on-Tangible-Equity Calculation

VivoSim Labs's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=-2.301/( (3.313+9.705 )/ 2 )
=-2.301/6.509
=-35.35 %

VivoSim Labs's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=-9.192/( (6.019+3.793)/ 2 )
=-9.192/4.906
=-187.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of -187.36% mean?
VivoSim Labs (FRA:4OR) has a Return-on-Tangible-Equity of -187.36% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on VivoSim Labs and its competitors. According to the industry distribution chart, VivoSim Labs ranks #440 out of 1201 companies in the Biotechnology industry, placing it in the top 36.6%.
Is VivoSim Labs' Return-on-Tangible-Equity too high?
VivoSim Labs' current Return-on-Tangible-Equity is -187.36%. Based on the distribution chart, VivoSim Labs ranks #440 out of 1201 companies in the Biotechnology industry, which is above the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Return-on-Tangible-Equity compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #440 out of 1201 companies for Return-on-Tangible-Equity. This puts VivoSim Labs in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current Return-on-Tangible-Equity is -187.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Return-on-Tangible-Equity of -187.36%. The stock's GF Value™ is €8.71, compared to a current price of €3.49 — trading 59.9% below its estimated fair value. The current Return-on-Tangible-Equity is -187.36%. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Return-on-Tangible-Equity is -187.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 59.9% below its estimated GF Value™ of €8.71.

Key valuation signals for FRA:4OR:

  • Return-on-Tangible-Equity: -187.36%
  • GF Value™: €8.71 vs. price of €3.49 (59.9% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score

Get the complete analysis for FRA:4OR

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€8.71
GF Value